cyc 202 has been researched along with Stroke in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, JH; Hwang, IK; Kang, IJ; Kim, DW; Kim, IH; Kim, YM; Lee, CH; Lee, JC; Lee, TK; Lee, YL; Park, JH; Ryoo, S; Shin, BN; Won, MH | 1 |
| Al Baradie, R; Alessandri, G; Ali, K; Bolton, D; Bosutti, A; Caccuri, F; Caruso, A; Krupinski, J; Kumar, S; Martinez-Gonzalez, J; Matou, S; Montaner, J; Pennucci, R; Petcu, EB; Qi, J; Rodriguez, C; Slevin, M; Tsai, LH | 1 |
| Bach, S; Blevins, TL; Campbell, M; Meijer, L; Menn, B; Timsit, S | 1 |
| Menn, B; Timsit, S | 1 |
4 other study(ies) available for cyc 202 and Stroke
| Article | Year |
|---|---|
Down-regulation of cyclin-dependent kinase 5 attenuates p53-dependent apoptosis of hippocampal CA1 pyramidal neurons following transient cerebral ischemia.
Topics: Animals; Apoptosis; CA1 Region, Hippocampal; Cyclin-Dependent Kinase 5; Ischemic Attack, Transient; Neuroprotection; Phosphorylation; Protein Transport; Pyramidal Cells; Retinoblastoma Protein; Roscovitine; Stroke; Tumor Suppressor Protein p53 | 2019 |
Targeting p35/Cdk5 signalling via CIP-peptide promotes angiogenesis in hypoxia.
Topics: Actin Cytoskeleton; Adaptor Proteins, Signal Transducing; Analysis of Variance; Blotting, Western; Cell Cycle Proteins; Cell Line; Cell Movement; Colorimetry; Cyclin-Dependent Kinase 5; Cytoskeleton; DNA Primers; Humans; Hypoxia; Immunoprecipitation; MEF2 Transcription Factors; Microarray Analysis; Microscopy, Fluorescence; Mutation, Missense; Neovascularization, Physiologic; Peptides; Pseudopodia; Purines; RNA Interference; Roscovitine; Signal Transduction; Stroke | 2013 |
Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.
Topics: Animals; Brain Ischemia; Cell Death; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 5; Disease Models, Animal; Drug Administration Routes; Humans; Injections; Male; Mice; Mitosis; Neuroprotective Agents; Purines; Rats; Roscovitine; Stroke; Time Factors | 2010 |
Cyclin-dependent kinase inhibition with roscovitine: neuroprotection in acute ischemic stroke.
Topics: Animals; Brain Ischemia; Clinical Trials as Topic; Cyclin-Dependent Kinases; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Models, Biological; Neuroprotective Agents; Protein Kinase Inhibitors; Purines; Roscovitine; Stroke | 2012 |